J&J Units Hit Mylan With IP Suit Over Concerta Generic Bid

Law360, Los Angeles (May 13, 2014, 6:52 PM EDT) -- Two Johnson & Johnson units filed a patent suit against drugmaker Mylan Inc. in Delaware federal court on Monday, alleging Mylan's bid to market a generic version of the Concerta attention-deficit hyperactivity disorder medication violates its patent.

Alza Corp. and Janssen Pharmaceuticals Inc. filed the suit Monday after Mylan told them in April that it had submitted an abbreviated new drug application with the Food and Drug Administration, seeking to make and sell a generic version of Concerta before the patent's expiration date. Alza owns the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.